Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Rectal Neoplasms × dalotuzumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 4 Breast Neoplasms 4 Neoplasms 3 Lung Neoplasms 3 Carcinoma, Non-Small-Cell Lung 3 Solid Tumors 1 Rectal Neoplasms 1 Pleural Effusion 1 Pancreatic Neoplasms 1 Ovarian Neoplasms 1 Neuroendocrine Tumors 1 Neoplasm Metastasis 1 Multiple Myeloma 1 Insulin-Like Growth Factor I, Resistance To 1 Fallopian Tube Neoplasms 1 Advanced Solid Tumors 1 Adenocarcinoma 1

Interventions

Fluorouracil 248 Oxaliplatin 243 Leucovorin 196 Capecitabine 195 Irinotecan 137 Radiotherapy 122 Bevacizumab 102 Cetuximab 71 Folfox protocol 46 Surgical Procedures, Operative 41 Drug Therapy 39 Neoadjuvant Therapy 38 Radiation 36 Chemoradiotherapy 33 Chemotherapy, Adjuvant 31 Panitumumab 25 XELOX 22 Radiotherapy, Intensity-Modulated 20 Floxuridine 17 Magnetic Resonance Spectroscopy 16 pembrolizumab 13 Laparoscopy 13 IFL protocol 13 trifluridine tipiracil drug combination 12 Nivolumab 12 Immunohistochemistry 12 Gemcitabine 12 Erlotinib Hydrochloride 12 Early Intervention, Educational 12 Celecoxib 12

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01609231 2020-05-04

MK-0646-025

Merck Sharp & Dohme LLC

Phase 2 Terminated

11 enrolled 8 charts

Gastrointestinal

Rectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡